FIELD: medicine.SUBSTANCE: invention can be used as a preventive and therapeutic agent with anti-inflammatory and antibacterial properties, intended for external use, for treatment of all kinds of chronic dermatoses: dermatitis, neurodermatitis, furunculosis, eczema, fungal diseases, parasitic skin diseases, acne, and method for its production. The external agent for treatment of chronic dermatitis in the form of an aqueous suspension of mercuric monochloride is prepared by a process comprising premixing of powdered mercury monochloride with nitric acid at the following ratio of components, wt %: mercury monochloride 0.3-0.6; nitric acid 0.6-1.0, at a temperature of 70-90°C, stirring for 1 hour. Then the obtained solution is mixed with water of high mineralization from the "Belaya Gorka" mineral source to 100 wt %. At that, the pH of the obtained suspension is adjusted to 1-2 with nitric acid.EFFECT: increased efficiency of treatment.2 cl, 7 ex
FIELD: biotechnology.SUBSTANCE: invention relates to biochemistry, in particular, to mutant HBV polymerase polypeptide containing a mutant HBV polymerase domain with the internal deletion that suppresses the polymerase functional activity, and mutant RNase H domain with the internal deletion and mutations that suppresses the functional activity of RNase H. This invention also relates to a hybrid protein containing the said mutant HBV polymerase polypeptide and core HBV polypeptide or immunogenic HBsAg envl and env2 domains. The said mutant polypeptide and hybrid proteins are used for induction or stimulation of the immune response against HBV. The present invention also discovers a nucleic acid molecule, an expression vector and a composition and kit for the treatment or prevention of the infection caused by HBV or HBV-associated diseases and of pathological conditions. The present invention also discloses the host-cell, a method of obtaining the hybrid proteins and a method of obtaining viral particles which uses the said expression vector.EFFECT: invention provides for improving the immunizing capacity of mutant HBV polypeptides preserving security when using them.46 cl, 11 dwg, 2 ex
FIELD: veterinary medicine.SUBSTANCE: method of producing a transfer factor for the prevention of viral bid diseases, comprising preparing lymphocytes extract, hydrolysis by DNA, dialysis with subsequent preservation or lyophilization the title product, wherein the spleen of vaccinated against one or more infections, or recovered chickens or chickens is taken as a lymphocyte source.EFFECT: efficient preparation of the transfer factor from an extract of lymphocytes with increased yield.2 tbl, 2 ex
FIELD: veterinary medicine.SUBSTANCE: way includes the injection of transfer-factor to the bird. Transfer factor is obtained from blood leukocytes vaccinated against one or more infections or outgrown their chickens or chickens. The drug is injected to the poultry of all ages aerosol melkodispersno one dose on the head upon exposure of 20-25 minutes. Aerosol producing distilled water with the addition of 10% glycerol to the volume.EFFECT: use of the claimed invention is highly effective for the prevention of infectious disease in birds and improve preventive vaccines.4 cl, 2 tbl, 3 ex
FIELD: pharmacology.SUBSTANCE: invention relates to a skin treatment agent having an anti-inflammatory, anti-bacterial, anti-viral, anti-fungal activity that is an oil extract of Gynura procumbens leaves obtained in a specific manner.EFFECT: agent is effective for skin diseases treatment.6 cl, 16 ex
FIELD: veterinary medicine.SUBSTANCE: clinically healthy calves 20-30 days of age are given xymedon hydrochloride mixed with a 3.5% alcohol tincture of scotch pine (Gemmue Pini) buds, herbs and inflorescences of Ehinacea purpurea L., rhizomes and roots of elecampane (Inula Neleium L.), taken in the ratio 2:1:1, calculated based on 2.0 g of xymedon hydrochloride to 100.0 ml of 3.5% alcohol tincture of scotch pine (Gemmue Pini) buds, herbs and inflorescences of Ehinacea purpurea L., rhizomes and roots of elecampane (Inula Neleium L.), dosed as 1.5-2.0 ml/kg of body weight for the first time 18-24 hours before and twice after immunization. The immunization is carried out three times by subcutaneous injection of hyperimmune serum containing antihaemagglutinin to viruses PG-3 in titer of 1:1280, IRT - in titer of 1:256 and VD-BS - in titer of 1:1024, adenovirus - in titer of 1:256, PC-virus - in titer of 1:128, dosed as 1.0 ml/kg body of weight at an interval of 10-12 days.EFFECT: higher preventive effect.4 tbl, 3 ex
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to gynaecology, and can be used for dynamic control of treatment of cervical intraepithelial lesions of cervix uteri. For this purpose after application of medication based on active substance 3,3'-diindolylmethane in dosage form "vaginal suppositories" in dose 200 mg/day for 6 months efficiency of therapy with application of colposcopic methods is assessed after 6 and 12 months of therapy.EFFECT: method makes it possible to reliably assess therapy efficiency and speed of onset of therapeutic effect.4 tbl, 5 ex
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition is made in the form of nasal cream containing an active substance of dioxotetrahydroxytetrahydronaphthalene and exicipients such as citric acid monohydrate, poloxamer 338, macrogol 20 cetostearyl ether, cetostearyl alcohol, solid paraffin, liquid paraffin, dimethicone 100 and propylene glycol.EFFECT: stability when stored at temperatures above 25 degrees.2 cl, 15 dwg, 7 tbl
FIELD: pharmacology.SUBSTANCE: invention relates to new synthetic compounds, namely 1-(1-adamantyl)ethylamide-3-(2-thienyl)-propenoic acid (TEPr-Rem) 1-adamantylamide-3-(2-thienyl)-propenoic acid (TEPr-Amt) and 1-(1-adamantyl)ethylamide-4-(2-thienyl)-butyric acid (TEBu-Rem) The proposed compounds: TEPr-Rem, TEPr-Amt and TEBu-Rem inhibit reproduction of pathogenic influenza virus A/H1N1pdm2009 and A/H5N1 strains, also provide virucidal effect against virus A/H5N1 influenza particles.EFFECT: increased activity of compounds.3 cl, 6 ex, 8 dwg
FIELD: medicine.SUBSTANCE: for specific prevention of measles, mumps, rubella for HIV-infected children, clinical, immunological and serological studies in HIV-infected children are conducted. Then, the primary immunization with live vaccines is carried out twice with an interval of 6 months. After 4 years, revaccination is performed, then every 4-5 years dynamic control of specific immunity to measles virus, mumps, rubella is performed. In the absence of protective antibod titres, re-introduction of vaccines/vaccine is performed.EFFECT: application of the proposed method will increase the efficiency of vaccination with live vaccines against measles, mumps, rubella, and significantly reduce the percentage of seronegative HIV-infected children.3 ex, 1 tbl
FIELD: pharmacology.SUBSTANCE: group of inventions discloses a pharmaceutical composition comprising of a mycophenolate salt covered with an enteric coating which provides the release of mycophenolate in the upper part of the intestinal tract, and a method of immunosuppression in a patient involving the administration of a therapeutically effective amount of said composition to a patient in need of such therapy.EFFECT: increased efficiency of the composition.15 cl, 2 ex, 1 tbl
FIELD: pharmacology.SUBSTANCE: invention relates to the antiviral agent based on the culture extract of "hairy roots" of Nitraria schoberi L., that is a dry plant extract. The dry plant extract contains dry extractives not less than 42.7%, the total protein not less than 28±6 mg/g, polysaccharides in the amount of not less than 205±17 mg/g, phenolic compounds in the amount of, at least, 9±1 mg/g, flavonoids in the amount of not more than 5 mg/g.EFFECT: expanding the raw material base for preparing antiviral agents and an assortment of antiviral agents relative to influenza A virus of subtypes H3N2 and H5N1.2 cl, 4 dwg, 5 tbl, 5 ex
FIELD: agriculture.SUBSTANCE: invention relates to the field of veterinary medicine and is intended for prevention of colibacillosis in calves. The immunization of down-calving cows is performed 1.5-2 months before the delivery with the vaccine against colibacillosis of animals Coli-Vack K88, K99, 987P, F41, TL- and TC-anatoxins twice with an interval of 15 days, the first dose is 10 cm3, the second is 15 cm3. The visceral novocaine blockade on L.G. Smirnov is performed to calves received from these cows within 1-2 hours after birth and on the 7th day of life.EFFECT: method increases the level of specific and non-specific humoral and cellular immunity of calves; reduces the incidence of colibacillosis.3 tbl, 1 ex
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, namely to immunology, and can be used for producing human papilloma virus vaccine. Vaccine composition against human papilloma virus includes: a) therapeutically effective amount of virus-like particles (VLP) HPV, adsorbed on aluminium adjuvant; b) mannitol and saccharose, c) optionally salt. Wherein composition contains: 1) virus-like particles HPV of at least one type, adsorbed on aluminium adjuvant, present in concentration equal to 10-200 mcg/ml, wherein virus-like particles are selected from group, consisting of: HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV45, HPV51, HPV52, HPV53, HPV55, HPV56, HPV58, HPV59, HPV66, HPV68, HPV73 and HPV82; and 2) from approximately 1 % to approximately 10 wt/vol. of mannitol; and 3) from approximately 0.5 % to approximately 10 % of sucrose. Composition is frozen or lyophilized and composition is stable at storage during 1 month at 25 °C after stress caused by process of lyophilization or freezing-thawing. Group of inventions also relates to methods of producing said vaccine.EFFECT: use of given inventions enables to obtain solid preparation of vaccine HPV (frozen or lyophilized) containing combination of excipients mannitol and saccharose, providing preservation of antigenicity of lyophilized vaccine preparation.21 cl, 9 ex, 3 tbl, 15 dwg
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to immunology, and can be used for production of rabies diagnostic serum. For that immunization of animals-producers with antigen material and adjuvant is made. As adjuvant mixture of lanolin and polyethylsiloxane liquid is used, taken in weight ratio 1:2–9, respectively, immunomodulator immunofan in amount of 0.8–1.2 ml per one animal is additionally used. Immunization is performed 5 times, wherein at first three times every 20–24 hours antigen is introduced together with adjuvant, taken in weight ratio 1:0.8–1.0 in amount of 10–14 ml of mixture of antigen with adjuvant per one animal and simultaneously – immunofan. Then 12–16 days later antigen is introduced in amount of 5–7 ml of antigen per one animal and simultaneous immunofan, then 7–8 days later antigen is introduced in amount of 5–7 ml of antigen per one animal. Besides, method of producing rabies diagnostic serum uses polyethyl siloxane liquid PES-2 or PES-3 as polyethylsiloxane liquid, and antigen material is "sheep" strain of rabies virus VGNKI and reference strain CVS.EFFECT: application of given method allows to increase target product quality due to increased specific activity of serum.4 cl, 5 ex
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is a polypeptide, comprising a Fc-domain of an antibody with at least one amino acid modification, which has high activity of binding with FcγRIIb in comparison with initial polypeptide, where value [value KD polypeptide containing Fc-domain of antibody against FcγRIIa (type R)]/[value KD polypeptide containing Fc-domain of antibody against FcγRIIb] is equal to or greater than 1.2, where value [value KD for higher activity of binding polypeptide containing Fc-domain of antibody against FcγRIIa (type R) and FcγRIIa (type H)]/[value KD for higher activity of binding initial polypeptide on FcγRIIa (type R) and FcγRIIa (type H)] is 0.7 or more, and where amino acid modification is a replacement of Pro in position 238 (EU numeration) with Asp or replacement of Leu in position 328 (EU numeration) with Glu. Described are methods of producing said polypeptide and use thereof.EFFECT: invention widens range of therapeutic and preventive agents.20 cl, 16 dwg, 12 tbl, 9 ex
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology. Strain Lactobacillus paracasei MCC1849 with high stimulating production of IL-12 activity.EFFECT: strain is used as ingredient of medicinal agent for immune stimulation, agent against influenza virus, food product, beverage, fodder and agent stimulating production of IL-12.8 cl, 2 dwg, 3 tbl, 3 ex
FIELD: pharmaceutics.SUBSTANCE: group of inventions refers to medicine and pharmacology, and can be used for preparing solid pharmaceutical composition, wherein the solid pharmaceutical composition contains: (i) amorphous solid solution of 9-[2-[bis[(pivaloiloxy)-methoxy]phosphinyl]methoxy]ethyl]adenine (AD) and a copolymer of vinylpyrrolidone and vinyl acetate and (ii) one or more pharmaceutically acceptable inactive ingredients selected from microcrystalline cellulose, silicon dioxide and magnesium stearate, wherein the solid pharmaceutical composition is stable, such that when the solid pharmaceutical composition is stored at 40 °C and relative humidity of 75 % in a closed container for 3 months, amount of impurities presented in the solid pharmaceutical composition, is not more than 0.74 weight. % in relation to the initial number of AD, wherein the admixture is 9-[2-(pivaloiloxy)-methoxyphosphinyl]methoxy]ethyl]adenine; at that, the method comprises the following steps: (i) producing amorphous solid solution of AD and copolymer of vinylpyrrolidone and vinyl acetate by dissolving the initial quantity of AD and copolymer of vinylpyrrolidone and vinyl acetate in a volatile organic solvent selected from ketones and halocarbons, evaporation of the volatile organic solvent and (ii) dry mixing of the obtained amorphous solid solution with one or more pharmaceutically acceptable inactive ingredients. Solid pharmaceutical composition and packing system are also disclosed.EFFECT: group of inventions ensures production of highly-stable composition having storage stability.10 cl, 5 tbl, 3 ex
FIELD: chemistry.SUBSTANCE: invention relates to a salt of a compound of formula wherein R1 denotes methyl, ethyl, butyl or cyclopropylmethyl, R2 denotes phenyl, where phenyl contains a substitute selected from a group, including trifluoromethoxy group and difluoromethoxy group, and R3 denotes hydrogen, methyl, chloro, methoxy group or trifluoromethyl, with organic sulphonic acid or its solvate, or hydrate, their solvates and hydrates and their use as antiviral agents.EFFECT: novel compounds.14 cl, 1 dwg, 4 tbl, 1 ex
FIELD: chemistry.SUBSTANCE: invention relates to compounds used in pharmaceutical compositions for treating diseases caused by dengue virus, having formulae: , where: R1 is aryl, where said aryl is phenyl or naphthyl, optionally substituted with one or three substitutes independently selected from a group consisting of following: C1-6alkoxy; R1a is C1-6alkyl; R1b is -OR1a or -N(R1a)2; R2a and R2b (i) are independently selected from a group consisting of following: hydrogen, C1-10alkyl, -(CH2)mC(=O)R1b and aryl-C1-3alkyl; R3 is C1-10alkyl or aryl-C1-3alkyl, where said aryl is phenyl; R4 is hydrogen; R6 is A, B, C or D, where R8 is hydrogen or C1-3alkyl; R5 and7 are independently selected from hydrogen, C(=O)C1-6alkyl; m ranges from 0 to 3; or its pharmaceutically acceptable salt.EFFECT: treating diseases caused by dengue virus.19 cl, 2 tbl, 2 ex
FIELD: chemistry.SUBSTANCE: invention relates to novel adamantane-containing amines of general formula, more specifically to 2-(adamant-2-yl)pentane-1-amine and 2-(adamant-2-yl)phenylethyl-1-amine, in general formula R=C3H7, C6H5.EFFECT: novel compounds exhibit antiviral activity.1 cl, 1 tbl, 2 ex
FIELD: pharmaceutics.SUBSTANCE: present invention relates to a compound and its pharmaceutically or cosmetically acceptable salts, used as an inhibitor of sodium-dependent glucose co-transporter, antioxidant and for depigmenting the skin in medicine and cosmetology, of the following formula (I): , as well as methods of its production and compositions based thereon, where n, m and p are independently 0 or 1, R denotes CH2OH or CH2OR11,R1 and R2 are OH or OR15, R3 is OH or OR18, R4 is a hydrogen atom, when n=1, or a hydrogen atom, a halogen atom or OH group, when n=0; X1 is a hydrogen atom, halogen atom, OH group, (C1-C6)-alkyl or OR24; U, V and W denote phenyl, pyrazolyl, N-(C1-C6)alkyl-pyrazolyl or thienyl optionally substituted by one or more substitutes selected from a halogen atom, OH, (C1-C6)-alkyl and OR24; R11, R15 and R18 are aryl-(C1-C6)-alkyl and R24 is (C1-C6)-alkyl or aryl-(C1-C6)-alkyl. In the proposed methods a compound of formula (II) is fluoridated, or compounds of formulae (VIII) and (XI) , are bound, wherein OH group in position of R4 in the binding product of formula (I) is optionally substituted by halogen, or the compound of formula (I) is bromated with subsequent reconstruction, or a compound of formula (XVI) is associated with a compound of formula (V), where R, R1, R2, R3, X1, U, V, W, n, m and p are given above, A1 is -Li or -Mg-Hal, Hal is a halogen atom, R9 is a leaving group.EFFECT: new agent is disclosed which is suitable for bleaching and depigmentation of skin, as an antioxidant, for inhibition of sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, and diseases, where such inhibition is effective, in particular in the treatment or prevention of diabetes and diabetes-related complications.21 cl, 69 ex, 11 dwg
FIELD: veterinary science.SUBSTANCE: present group of inventions relates to veterinary science and concerns improving viability and stimulation of body weight gain of agricultural animals, mammals and birds. Method comprises administering a composition containing activated potentiated antibodies to insulin receptor, or insulin receptor and gamma-interferon, or insulin receptor, gamma interferon and CD4 receptor, or insulin receptor and CD4 receptor.EFFECT: introduction of said compositions provides higher productivity of farm animals with no side effects.14 cl, 17 tbl, 2 dwg, 7 ex
FIELD: veterinary science; biotechnology.SUBSTANCE: invention relates to veterinary virology and biotechnology. Vaccine contains active substance and target additives. As active substance, vaccine contains mixture of avirulent purified antigen material of foot FMD A strains No. 2171/Kabardino-Balkar/2013, A No. 2187/Kuti/2013, Asia-1 No. 1946/Shamir 3/89 and O No. 2123/South Ossetia/2011, obtained from transplantable cell culture VNK-21, representing suspension, containing mainly 146S and 75S immunogenic components of FMD, adjuvants: aluminium hydroxide with saponin and preserving medium in effective ratios.EFFECT: vaccine exhibits high immunogenicity and is capable of providing effective protection against homologous infectious agents, circulating in Transcaucasus, Central Asia, middle and Near East.16 cl, 4 dwg, 7 tbl, 5 ex
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to neurology, and can be used for treating patients with focal form of mixed encephalitis-borreliosis infection in acute period. For this purpose at background of etiotropic and pathogenetic therapy intravenous introduction of normal human immunoglobulin is made in daily dose of 2.5 g in course of 3-5 days, inclusive, regardless of day of disease.EFFECT: method allows reducing risk of residual neurological deficiency due to formation of own active specific immunity at low probability of protein overload.1 cl, 2 tbl, 2 ex
FIELD: medicine.SUBSTANCE: invention refers to medicine and is aimed at treating patients with facial pain with postherpetic ganglionitis of a head. Content of specific G antibodies to the herpes simplex virus (HSV) type 1 and cytomegalovirus, content of alpha and gamma interferons, serum and spontaneous interferon in blood, in the oral fluid: concentration of A secretory immunoglobulin, alpha interferon and lactoferrin level. Index of microorganisms adsorption reaction is calculated (MAR). If the values of serum and spontaneous interferon do not exceed 2 units/ml, content of specific G antibodies to HSV type 1 is from 1:2973.75 and higher, to cytomegalovirus - from 1:2916.91 and higher, of alpha interferon - from 194.78 unit/ml and lower, of gamma interferon - from 16.87 unit/ml and lower, and in the oral fluid: concentration of secretory immunoglobulin - from 225.11 mg/ml and lower, concentration of alpha interferon - from 8.6 pg/ml and lower, lactoferrin level - from 9613.3 ng/ml and lower, MAR index - from 6.5 and higher, the acyclic nucleosides group drug is prescribed in complex, anti-inflammatory agents, anti-histamine drugs, immunomodulators.EFFECT: using the invention provides increase in treatment efficacy due to comprehensive application of drug therapy preparations.1 cl, 1 ex
FIELD: chemistry.SUBSTANCE: invention relates to a compound of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalene-2-yl)methanesulfonamide or its pharmaceutically acceptable salt for use as a medicinal agent for inhibiting replication of hepatitis C virus (HCV), as well as to a medicinal agent containing a therapeutically effective amount of the said compound or its pharmaceutically acceptable salt.EFFECT: technical result is stable indices of efficiency of treating, relieving symptoms of hepatitis C, providing partial or complete reduction of symptoms.5 cl, 46 dwg, 40 tbl, 140 ex
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used for inducing cross-protection against at least one heterosubtypic strain of influenza. To induce cross-protection against at least one heterosubtypic strain of influenza in comparison with influenza strains, antigens of which are present in influenza vaccine, influenza vaccine containing and HA and NA is administered. Where vaccine is a virosomal influenza vaccine, which does not contain an auxiliary agent and which is administered intramuscularly at least three times in one year. Group of inventions also relates to a method of inducing cross-protection against influenza H5N1 strain and to a method for influenza vaccination.EFFECT: use of present group of inventions makes it possible to provide cross-protection due to administration of virosomal seasonal vaccines, which do not contain an auxiliary agent by normal intramuscular administration.13 cl, 7 ex, 9 dwg
FIELD: medicine.SUBSTANCE: invention refers to medicine and concerns new therapeutic regimens of acute viral hepatitis treatment, making it possible to reduce duration of clinical manifestation and preventing transition in the chronic course of the disease. Method of treating acute hepatitis B or C with severe clinical course consists in intravenous drop introduction of preparation 2 times a week for three months, wherein first drop introduction is 4.0 ml of Laennek, dissolved in 250 ml of 0.9 % sodium chloride water solution or 5 % glucose solution, through ulnar vein for 1 hour 20 minutes, second and subsequent introductions consist 10.0 ml of Laennek, dissolved in 250 ml of 0.9 % saline solution through ulnar vein for 1.5 hours.EFFECT: method of treating acute hepatitis B or C is disclosed.1 cl, 2 ex
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to immunology, and can be used for producing of chimeric immunoglobulin preparation with specific antiviral or antibacterial effect. Chimeric immunoglobulin preparation contains immune proteins from milk and/or colostrum from immunized cows and stabilizing additives. Chimeric partially humanized bovine secretory immunoglobulin A (S-IgA) is used as immune protein, in which bovine secretory component is substituted by recombinant or donor human secretory component.EFFECT: using this composition allows to create high-purity immunoglobulin preparation based on S-IgA with reduced immunogenicity and reactogenicity suitable for oral, parenteral and local adminstration.3 cl, 5 ex
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine. Method for prevention and/or treatment of viral infections, involving administering the composition. Disclosed is a composition of high-purity extract yeast RNA having weight not less than 75 % of fragments 25±10 nucleotides, with purity preferably at least 99 %, in combination with mannitol in the ratio of 2:1 to 3:1, where the extract yeast RNA is preliminarily heated mannitol, the extract of yeast RNA is not less than 50 % of composition weight. Disclosed is a method of preparing said composition.EFFECT: presented group of inventions provides the new antiviral agent with prolonged action.28 cl, 15 dwg, 14 tbl, 2 ex
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to immunology, and can be used composition for treating persistent infection, angioimmunoblastic lymphoma or nodular lymphocyte predominant Hodgkin lymphoma. Composition contains a PD-1 activity or expression inhibitor. Group of inventions also relates to a composition containing an antigen-specific T-cell, brought into contact with a compound which reduces expression or activity of PD-1.EFFECT: using present group of inventions enables to block expression level of PD-1, which leads to increased CD8+ T-cell proliferation.21 cl, 8 dwg, 1 tbl, 14 ex
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to virology, and can be used for achieving prolonged clinical remission of chronic HPV infection, manifesting condyloma of anogenital region. Method includes triple vaccination of patients against 6, 11, 16 and 18 HPV types with "Gardasil" preparation for 0-2-6 months. Simultaneously applying 5 % Aldara cream on condyloma 3 times a week before bedtime, with subsequent washing in morning with soap until disappearance of visible anogenital warts, but not more than 16 weeks. Aldara 5 % cream is applied on day of first dose of "Gardasil" vaccine.EFFECT: invention provides clinical recovery of pointed condylomas and prevents repeated infection with condyloma types of HPV.1 cl
FIELD: medicine.SUBSTANCE: invention relates to a medicinal agent with antiviral activity with respect to HIV infection and hepatitis B virus, which is a derivative of 2-chloro-5-phenyl-5H-pyrimido[5′,4′: 5,6]pyrano[2,3-d]pyrimidin-4-ol of general formula (I) , where X is selected from a group of H, NO2, Hal, OMe; R1 is selected from: Cl, OH; R2 is selected from: Cl, SH, OH. Therapeutic agent can contain effective amounts together with a compound of formula (I) reverse transcriptase inhibitor, selected from Retrovir, or protease inhibitor selected from Lopinavir.EFFECT: drug can be prepared in form of tablets or capsules for enteral reception or in form of lyophilic dried substance; or in form of rectal suppositories.2 cl, 9 tbl, 6 ex
SUBSTANCE: invention relates to pharmaceutical industry and represents use of antibacterial and antiviral pharmaceutical composition, having pronounced anticancer, antibacterial and antioxidant properties, containing silver nitrate, hexamethylenetetramine, sodium thiosulphate, alpha-aspartic acid or asparagine, nicotinic acid and water, wherein ingredients of composition are taken in a certain ratio, wt%, and also represents use of antibacterial and antiviral pharmaceutical composition, having pronounced anticancer, antibacterial and antioxidant properties, containing silver nitrate, hexamethylenetetramine or imidazole, alpha-aspartic acid or asparagine, nicotinic acid, imidazole-containing compounds of platinum cis-[Pt (NH3)2Im2]Cl2 or CIS-[Pt (NH2OH)2Im2]Cl2 and water, wherein ingredients of composition are taken in certain ratio, wt%.
EFFECT: invention widens range of agents for said purpose, wherein claimed composition can be used as an integral part or as independent preparation, having therapeutic and preventive properties, preventing damage to cells by free radicals, improving body defences and promoting tissue regeneration.
2 cl, 2 ex, 1 tbl
SUBSTANCE: group of inventions refers to medicine and concerns method of activating telomerase, elongation of the telomeres and increasing capacity of the cell division, involving administering a composition containing a compound such as tetra-peptide, and at least one thymic peptide selected from group of dipeptide tripeptide, tetra-peptide or pentapeptide and/or peptide epiphysis, selected from a group dipeptide tripeptide, tetra-peptide or pentapeptide. Group of inventions also concerns a composition for activation of telomerase, elongation of telomeres and increasing capacity of cell division; using said composition for producing agent for preventing and/or treating conditions, for which is useful telomerase activation, elongation of telomeres and increased capacity of cell division.
EFFECT: group of inventions provides activation of telomerase, elongation of telomeres and increased capacity of cell division.
30 cl, 9 ex
SUBSTANCE: described are 3 versions of antiviral and immunostimulating drugs in form of a film-coated tablet, consisting of active substance methylphenylthiomethyl-dimethylaminomethyl-hydroxybromoindole carboxylic acid ethyl ester (umifenovir), auxiliary substances of tablet-core and film shell.
EFFECT: higher storage stability of said drug.
18 cl, 4 tbl
SUBSTANCE: invention refers to pharmaceutical industry, particularly to medicinal composition, possessing antibacterial action. Natural drug formulation possessing antibacterial action in relation to bacteria of poultry origin, contains herbal active ingredient based on tannin in combination with carriers, said herbal active ingredient is natural extract chestnut (Castanea sativa). Drug cream. Drug powder. Dosage ointment. Dosage suspension. Medicinal capsules. Application of medicinal composition.
EFFECT: compositions described above possess pronounced antibacterial action in relation to bacteria of poultry origin.
7 cl, 2 tbl, 2 ex
SUBSTANCE: invention relates to an agent possessing immunomodulatory and antiviral action. Agent having immunomodulatory and antiviral action in form of an ointment, which contains medical vaseline, anhydrous lanolin, peach oil, alpha-tocopherol acetate, human recombinant interferon alpha-2b, ascorbic acid, human serum albumin solution 10 %, calcium pantothenate, purified water, taken in a certain amount.
EFFECT: said agent possesses pronounced immunomodulatory and antiviral action, is stable during storage.
1 cl, 5 ex
FIELD: medicine.SUBSTANCE: disclosed are compositions for injection and infusion solutions of antiviral preparation wide range of action - L-arginine salt of 5-methyl-6-nitro-1,2,4-triazolo[1,5-a]pyrimidin-7-one monohydrate, including auxiliary components. Infusion and injection solutions of L-arginine salt of 5-methyl-6-nitro-1,2,4-triazolo[1,5-a]pyrimidin-7-one monohydrate are based on use of solubilisers of Glutamine type, which increases solubility of main medicinal component and its bioavailability in tissues in a vascular bed. Introduction of Glutathione and Carnosine is linked with their ability to stabilise cell metabolism of Z-arginine salt of 5-methyl-6-nitro-1,2,4-triazolo[1,5-a]pyrimidin-7-one monohydrate and increasing viability of infected cells.EFFECT: injection and infusion forms of antiviral preparation based on L-arginine salt of 5-methyl-6-nitro-1,2,4-triazolo[1,5-a]pyrimidin-7-one monohydrate are intended for treating severe forms of viral infections in accordance with pharmacological profile of antiviral activity and primarily complicated by influenza.2 cl, 2 ex, 2 tbl, 1 dwg
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to experimental virology, and can be used to inhibit infectious activity of Ebola virus in experiment. Method involves introduction to Guinea pigs preparation of recombinant human interferon alpha-2 before or during penetration agent in animal's body in daily dose sufficient for developing antiviral agent inhibiting activity. For this purpose, preparation “Reaferon-Lipint” in liposomal form is used in daily dose from 200,000 to 300,000 IU/kg. When simulating prevention and treatment of viral infection this preparation is introduced for 12 and 1 hours to virus infection inoculation of Ebola virus, at moment of infection and through 12, 24, 36, 48, 60, 72 hours after infection of Ebola virus.EFFECT: method provides achievement of inhibitory effect at reduction of preventive and therapeutic dose of recombinant human interferon alpha-2.2 cl, 3 tbl, 2 dwg
FIELD: medicine.SUBSTANCE: invention relates to medicine, specifically to gynaecology, Immunology and infectious diseases, and concerns treating recurrent genital herpes in females. That is ensured by antiviral drug acyclovir 800 mg 4 times a day for 5 days and immunomodulators - normal human immunoglobulin 3 ml intramuscularly every second day - 5 injections and administered 20 mg once a day for 5 days. Treatment is started for 5 days before expected recurrence.EFFECT: such regimen of administering preparations prevents developing manifested clinical signs of disease and provides achievement of stable remission.1 cl, 3 ex
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, in particular to an antiviral agent. Antiviral agent, based on extract of basidiomycete Coprinus comatus (O.F. Müll.) Pers., which contains a dry extract of said fungus, prepared by drying ethanol extract of biologically active substances, ground and homogenised feed components at a certain content in dry extract of aqueous solution in which concentration of at least 1.0 mg/ml has antiviral activity against RNA genome of influenza A virus subtypes H3N2 and H5N1.EFFECT: described agent is effective against RNA genome of influenza A virus subtypes H3N2 and H5N1.1 cl, 6 tbl, 5 ex
FIELD: chemistry.SUBSTANCE: invention relates to a novel form of [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]mono[3-(hexadecyloxy)propyl]ester of phosphonic acid, characterised by an X-ray diffraction pattern which includes peaks at angles 2θ of about 5.5, 19.3, 20.8 and 21.3 degrees and a purity of more than 91%, which can be used in the pharmaceutical industry, as well as to a method for production thereof. The disclosed method includes reacting cytosine with (S)-trityl glycidyl ether in the presence of a metal carbonate to form (S)-N1-[(2-hydroxy-3-triphenylmethoxy)propyl]cytosine; reacting (S)-N1-[(2-hydroxy-3-triphenylmethoxy)propyl]cytosine with a sodium salt of mono[3-(hexadecyloxy)propyl]ether of p-[[[(4-methylphenyl)sulphonyl]oxy]methyl]phosphonic acid in the presence of magnesium di-tert-butoxide to form [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)-2-(triphenylmethoxy)ethyl]methyl]mono[3-(hexadecyloxy)propyl]ester of phosphonic acid; removing the protective group to obtain [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]mono[3-(hexadecyloxy)propyl]ester of phosphonic acid and re-crystallisation thereof from methanol, ethanol, isopropanol, methanol:acetone:water, methanol:acetone or methanol:water systems.EFFECT: disclosed is a novel form of a biologically active compound, which is convenient for producing prodrugs, and a novel efficient method for production thereof.17 cl, 9 dwg, 14 ex, 22 tbl
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely, to application of the sum of flavonoids of roots or above-surface parts of Alchemilla vulgaris L. as an antiviral agent apropos RNA-containing virus of flu A and DNA-containing orthopoxviruses and virus of herpes simplex of type 2. Use of the the sum of flavonoids of roots and above-surface parts of Alchemilla vulgaris L. (alchemillae Herba) obtained by extraction of roots with the help of ethyl acetate, combination of ethyl acetate extract, concentration of it by evaporation and deposition of the concentrate in chloroform or extraction of an elevated part of alchemillae Herba collected at the beginning of blooming by ethanol, followed by combination and evaporation of the extract, dilution of it with distilled water, cleaning of the water extract with chloroform, extraction of the purified water residue with ethyl acetate, evaporation of the obtained extract and deposition of the product with chloroform under certain conditions as an antiviral agent apropos RNA-containing virus of flu A and DNA-containing orthopoxviruses of herpes simplex of type 2.EFFECT: above described sum of flavonoids is effective as an antiviral agent apropos RNA-containing virus of flu A and DNA-containing orthopoxviruses of herpes simplex of type 2.1 cl, 7 tbl, 7 ex
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely, to an antiviral agent based on the extract of basidiomycete Bjerkandera adusta (Willd.) P. Karst representing dry extract of mycete prepared by drying an aqueous extraction of biologically active substances of crushed and homogenised raw material with a certain content of components in the dry extract.EFFECT: substance described above has antiviral activity apropos RNA-genome virus of influenza A of subtypes H1N1, H3N2 and H5N1.1 cl, 6 tbl, 4 ex
FIELD: medicine.SUBSTANCE: effective treatment and prevention of various infectious viral diseases are ensured by administering a medicinal agent containing an activated potentiated form of anti-human gamma-interferon antibodies in a combination with an activated potentiated form of anti-CD4 T-lymphocyte receptor antibodies.EFFECT: effective treatment of infectious, including viral diseases ensured by synergetic action of the components of the medicinal agent.14 cl, 7 tbl, 5 ex
FIELD: medicine.SUBSTANCE: combined vaccine contains a first BVDV of the first type carrying E2 BVDV gene of the above first type, a second BVDV of the first type, wherein this E2 BVDV gene of the above first type is substituted by E2 BVDV gene of the second type, and a pharmaceutically acceptable carrier. The group of inventions also refers to a method for producing the above BVDV vaccine.EFFECT: using the chimeric BVDV vaccine containing original E2 gene, and also the second E2 gene of the other type ensures equal expression levels of both E2 genes.12 cl, 4 ex, 1 tbl, 6 dwg
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, particularly to pharmacology and aspects of treating or preventing upper airway disorders, and describes an inhalable dry powder containing dry particles containing magnesium salt, as well as methods of treating a respiratory disease, treating a respiratory disease attack, treating or preventing an upper airway infection with the above methods involving administering an effective amount of the inhalable dry powder into the airway of the patient in need thereof. The particles according to the invention have high dispersive ability, no tendency for clustering despite its small size, and contain high concentrations of the active ingredient.EFFECT: invention is applicable for therapy of upper airway diseases, as well as for making a medicinal preparation for treating, preventing, diagnosing upper airway disorders and/or infections.25 cl, 37 dwg, 40 tbl, 26 ex
FIELD: chemistry.SUBSTANCE: invention relates to the novel gossypol derivatives which can be used in pharmacology, having the general formula (I): where RI=Sach; RII=Sach or H; Sach is an oxidised polysaccharide residue, having a unit of one of the formulae given below: where n denotes the polymery of a compound containing from 1 oxidised unit per 1000 saccharide units of polysaccharide to completely oxidised polysaccharide, where the polysaccharide is selected from carboxymethyl cellulose or dextran, and the weight-average molecular weight Mw of 1 to 2000 kDa, preferably 3 to 80 kDa. Disclosed are novel gossypol derivatives with antiviral activity and an efficient method for production thereof, which includes reacting an oxidised polysaccharide having units of formulae: containing from 1 oxidised unit per 1000 saccharide units of polysaccharide to completely oxidised polysaccharide, with gossypol at pH 3.5-14 and molar ratio of gossypol:oxidised polysaccharide unit of 10:1 to 1:100.EFFECT: improved properties of the composition.10 cl, 5 tbl, 4 dwg